8.11
-0.43(-5.04%)
Currency In USD
| Previous Close | 8.54 |
| Open | 8.41 |
| Day High | 8.49 |
| Day Low | 8.03 |
| 52-Week High | 19.5 |
| 52-Week Low | 1.8 |
| Volume | 92,878 |
| Average Volume | 359,109 |
| Market Cap | 75.04M |
| PE | -3.08 |
| EPS | -2.63 |
| Moving Average 50 Days | 8.87 |
| Moving Average 200 Days | 6.74 |
| Change | -0.43 |
If you invested $1000 in CervoMed Inc. (CRVO) 10 years ago, it would be worth $0.07 as of September 16, 2025 at a share price of $8.11. Whereas If you bought $1000 worth of CervoMed Inc. (CRVO) shares 5 years ago, it would be worth $120.15 as of September 16, 2025 at a share price of $8.11.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
CervoMed to Participate in the Canaccord Genuity 45th Annual Growth Conference
GlobeNewswire Inc.
Aug 05, 2025 12:00 PM GMT
BOSTON, Aug. 05, 2025 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical stage company focused on developing treatments for age-related neurologic disorders, today announced that Company management will participate in a fireside chat and
CervoMed Announces 32-Week Data from RewinD-LB Trial Extension Phase Showing Neflamapimod’s Sustained Effect on Slowing Clinical Progression in Patients with Dementia with Lewy Bodies and Associated Reduction in a Key Plasma Biomarker of Neurodegeneration
GlobeNewswire Inc.
Jul 28, 2025 11:00 AM GMT
Based on the primary endpoint of Clinical Dementia Rating Sum of Boxes (CDR-SB), patients treated with neflamapimod showed 54% risk reduction in clinically significant worsening compared to control at Week 32 of treatment (p=0.0037). This risk reduct
CervoMed to Present New Data from Phase 2b RewinD-LB Study at AAIC 2025 and Host Conference Call on July 28, 2025
GlobeNewswire Inc.
Jul 24, 2025 8:05 PM GMT
Company to share primary endpoint results at 32-Weeks from Extension phase following late-breaking presentations at Alzheimer's Association International Conference® (AAIC) 2025 Conference call and webcast to be held Monday, July 28 at 8:00 AM ET BOS